6BX.F - Relevium Technologies Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0503
-0.0031 (-5.81%)
As of 8:14AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0534
Open0.0503
Bid0.0496 x 1700000
Ask0.0606 x 1400000
Day's Range0.0503 - 0.0503
52 Week Range0.0400 - 0.1100
Volume25,000
Avg. Volume1,141
Market Cap7.557M
Beta (3Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire5 hours ago

    Relevium to Hold Investor Call to Discuss LATAM Strategy June 28, 2019 at 1:00pm EST

    Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”), is pleased to announce it will be holding a shareholder and investor conference call to discuss its Latin American (LATAM) strategy and the upside potential of its recently announced acquisition in Colombia. It is estimated that Colombia is positioned to supply about 44% of the World’s market for medical cannabis and the acquisition of Lifeline Pharma SAS  (“LifeLine”) in Colombia is set to allow Biocannabix Health Corporation to target two important sources of revenues: (1) EU GMP pharma-grade extracts for export and (2) endo-nutraceutical (ENS) and oral nutritional supplements (ONS) for in-country distribution.

  • GlobeNewswire6 days ago

    Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali, Colombia

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS, a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia. Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.

  • GlobeNewswire8 days ago

    Relevium Closes Private Placement Financing

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has closed a non-brokered private placement financing for a total of 15,350,000 units (the "Units") at $0.08 per Unit, for total gross proceeds of $1,228,000. Each Unit consists of one common share of Relevium and one common share purchase warrant entitling the holder to purchase one additional common share at $0.12 per share for a period of one year from the date of the issue. Relevium has the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Relevium’s common shares is equal to or greater than $0.15 for 10 consecutive trading days.

  • GlobeNewswire14 days ago

    Relevium’s Biocannabix Executes LOI to Acquire 30% Interest in Weedsense, a Late Stage Applicant for Standard Processing and Medical Sales License

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly owned subsidiary Biocannabix Health Corporation (“Biocannabix”) has executed an LOI to acquire 30% of Weedsense Inc., a late stage applicant for standard processing and medical sales license. Weedsense Inc. (“Weedsense”) is building a wholesale and distribution business in Montreal, Québec.

  • GlobeNewswire16 days ago

    Relevium Provides Corporate Update on Its Medical Cannabis Strategy

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide a corporate update on the Company’s positioning and strategy regarding medical cannabis and CBD Nutraceuticals. The Food and Drug Administration (the “FDA”), held a key public hearing last Friday regarding its role in regulating cannabis-derived products such as CBD as nutritional supplements. The FDA’s position is that although hemp is no longer an illegal substance under federal law, the FDA continues to regulate cannabis products under the Food, Drug, and Cosmetic Act (“FD&C Act”) and Section 351 of the Public Health Service Act.

  • GlobeNewswire26 days ago

    Relevium Launches New Line of High-End Omega Fish Oils Targeting Inflammation, Heart and Vision    

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its OTC business has launched a new line of omega fish oils based formulations targeting inflammation, heart and vision care. The Company has launched an initial two omega formulated products to support heart health and vision care: CardiaProtm and VisionProtm, leading the way to a complete line of scientifically formulated products targeting inflammation. Inflammation, which is a process by which the body's natural immune response seeks to protect us from infection with foreign organisms, such as bacteria and viruses.

  • GlobeNewswire29 days ago

    Relevium Announces Private Share Purchase by CEO

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that Mr. Aurelio Useche, Chief Executive Officer, has agreed to purchase a total of 4,213,713 common shares of Relevium, representing approximately 3% of Relevium’s total shares outstanding, from Mr. Albertus Engelbrecht in a private transaction. Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the Health and Wellness markets and medical cannabis.

  • GlobeNewswirelast month

    Relevium Announces Reprice of the 2016 and 2017 Series Warrants

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced the re-pricing 12,398,500 warrants series 2017 with an original exercise price of $0.15 and expiring June 16, 2019 and 3,258,000 warrants of series 2016 with an original exercise price of $0.15 and expiring August 16, 2019. The series 2016 and 2017 have been repriced to $0.10 and the new exercise price is only valid for a period of 29 days starting today and expiring June 15, 2019. The warrant re-price is subject to final approval by the TSX Venture Exchange.

  • GlobeNewswire4 months ago

    Relevium Reports Second Quarter Revenue Bounce Back for Fiscal 2019  

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results for fiscal 2019. During the second quarter ended December 2018, the Company’s revenue bounced back to $1,006,501 as compared to $968,474 in the second quarter of fiscal 2018. The Company also reported quarter-over-quarter increase in revenues from $985,051 reported for the first quarter of fiscal 2019.

  • GlobeNewswire4 months ago

    Relevium Announces DTC Eligibility for the US Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC. DTC is a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly traded companies in the United States. DTC eligibility will simplify the process of trading and is expected to enhance liquidity and overall visibility in the US OTC capital markets, where the Company trades under the symbol "RLLVF".

  • GlobeNewswire4 months ago

    Relevium Launches the Push and Pull System™, Targeting a New Revenue Stream in the Burgeoning Cosmeceutical Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the new launch of the Push and Pull System™, an innovation in delivering a comprehensive solution for skin care, designed specifically for today’s active women. The Push & Pull System™ by Bioganix® is the first ever comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new launch is targeting a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.

  • GlobeNewswire5 months ago

    Relevium Announces Investor Web Conference

    Relevium Technologies is pleased to host a town hall information web conference to discuss the company’s developments and answer shareholder inquiries. During the webcast, management will be discussing business development initiatives, product launches and expansion of the Bioganix® brand, the acquisition of Sleipnir and update on the progress of initiatives launched late last year. The Company will also discuss the roll out of the LeefyLyfe™ brand and the newly acquired license for Cannakids® by its Biocannabix business unit.

  • GlobeNewswire5 months ago

    Relevium to Acquire Multi-Brand Company in the UK

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a binding agreement to acquire 100% of the shares of Sleipnir Nutrition Ltd. (“Sleipnir”), a UK health and wellness multi-brand portfolio entrepreneurial company with products in superfood teas, skin care and beauty. The transaction is expected to close before the end of this month. “We are excited to continue to strengthen our branding and global reach capabilities with the strategic acquisition of Sleipnir,” stated Abis Hussain, Chief Marketing Officer of Relevium.

  • GlobeNewswire5 months ago

    Relevium To Host Screenings of Documentary “Weed The People” Across Canada Today -- CFN Media

    In partnership with Executive Producer Ricki Lake, Director Abby Epstein, and CannaKids.org, Relevium will host a nation-wide screening of this compelling, emotional, and educational film that explores the potential benefits of medical cannabis oils for pediatric applications, followed by live discussions. The film follows the journey of five families with children battling cancer, and the introduction of cannabis oil into their treatment after the failure of conventional methods. “The film is an amazing journey into the potential opportunities of complementing traditional treatments for cancer and other illness in pediatric patients,” said Aurelio Useche, CEO of Relevium Technologies.

  • GlobeNewswire5 months ago

    Relevium Announces the National Screening of “Weed the People” Movie Across Eight Major Cities

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the national screening of “Weed the People” across eight Canadian cities on January 15, 2019. Relevium Technologies, in partnership with Executive Producer Ricki Lake, Director Abby Epstein and Cannakids.org, will be conducting a nation-wide screening of Weed the People, a compelling, emotional and educational film that explores the potential benefits of medical cannabis oils for pediatric applications. The film follows the journey of five families dealing with children suffering from cancer and the introduction of cannabis oil to treat their children following the failure of conventional treatments.

  • GlobeNewswire6 months ago

    Relevium Provides Corporate Update

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide shareholders with a corporate update on the previously announced transaction with CannaKids and CK properties, as well as to announce an additional  convertible note financing with our partners under the June 2017 note purchase agreement. In order to comply with TSX Venture Exchange policies regarding investments into US based Cannabis assets, Relevium Technologies would like to announce that it has renegotiated and restructured the transaction as announced on October 16, 2018. In the original transaction, the Company announced that it would acquire an initial twenty five percent (25%) of the outstanding shares in CK Properties and its brand CannaKids and will concurrently obtain the Canadian exclusive rights for a total consideration of USD$2.7 million.

  • GlobeNewswire6 months ago

    Relevium Launches Its Leefylyfe™ Organically Sourced Whole Plant Hemp Derived CBD Products in the UK

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has launched its  Leefylyfe™ brand of organically sourced full spectrum hemp CBD products on a pre-order basis in the UK. The Company is launching three initial organically sourced, whole plant Hemp CBD rich oils in product and tincture formats that maintain a full spectrum of secondary cannabinoids, terpene profiles and flavonoids for wellbeing. The company plans to launch several exclusive formulations of its Leefylyfe™ branded products in 2019 and plans to extend sales to the rest of Europe.

  • GlobeNewswire6 months ago

    Relevium Launches 30 New Bioganix® Gold Brand Products in Walmart.com

    On October 11, 2018, the Company announced it was targeting to launch 30 new products under its Bioganix® Gold Brand, which sell exclusively in Walmart.com. The Company has launched 14 out of the 30 new products and the balance is currently under the normal compliance review process and are expected to be live on Walmart.com and available to Walmart Shoppers over the next two weeks. “We are very excited about the addition of 30 new products to our Bioganix® Gold Line of nutraceuticals and skin care products sold exclusively through Walmart.com.

  • GlobeNewswire6 months ago

    Relevium Adds Amazon Experts to the Team

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has retained Rohan Mendonza and his company, NForce Labs Inc., to lead its Amazon business. Rohan Mendonza, formerly Director of Operations at Amazon.com Inc., is the CEO of NForce Labs, Inc., an e-commerce consulting firm helping brands streamline supply chains, grow organic marketing, and optimize paid advertising services with the goal of maximizing clients’ return on investment.

  • GlobeNewswire7 months ago

    Relevium Technologies Provides Corporate Update and Summarized First Quarter Results

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide a corporate update and summarized discussion on the results for its first quarter. Subsequent to the announcement made on October 16, 2018 on the Company’s letter of intent regarding CK Properties and its intellectual property including the Cannakids brand of pediatric medical cannabinoid formulations, the Company is please to announce it has received conditional approval by the TSX Venture exchange for the Canadian Licensing portion of the transaction. During the first quarter ended September 30, 2018, the Company’s topline revenues were impacted by major changes in Amazon’s Algorithm, which affected overall rankings and PPC spending for all sellers.

  • GlobeNewswire7 months ago

    Relevium Technologies Signs JV With Holistic Industries for Biocannabix Health Corporation

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has executed a letter of intent to form a partnership with Holistic Industries to jointly develop Biocannabix Health Corp, the pediatric and geriatric focused biopharma subsidiary of Relevium Technologies. “We are very pleased to partner with one the pioneers and leaders in medical cannabis in the US. The win-win strategy of leveraging the many years of experience from Holistic in growing and processing will allow the company to focus on research and product development dramatically shortening the development cycle and enabling the company to provide real medicine faster to patients in need,” said Aurelio Useche, CEO.